Abbott’s Plan For DBS Depression Therapy Wins FDA’s Breakthrough Designation
Abbott continued St. Jude Medical’s prior research on deep brain stimulation for treating depression and has advanced the technology far enough that the US FDA now believes it could be a breakthrough treatment for treatment-resistant depression.
You may also be interested in...
The US FDA approved Abbott's system that allows physicians to communicate with patients and remotely program their neuromodulation device.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.